An assessment of extended pembrolizumab dosing in advanced non-small-cell lung cancer in the COVID-19 pandemic
Description
Background: There are limited clinical data comparing extended dosing (ED) versus standard dosing (SD) of pembrolizumab for metastatic non-small-cell lung cancer. Methods: This retrospective study included patients with metastatic non-small-cell lung
